Guselkumab
- Generic Name
- Guselkumab
- Brand Names
- Tremfya
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1350289-85-8
- Unique Ingredient Identifier
- 089658A12D
- Background
Guselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23. IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation . In clinical trials, guselkumab demonstrated improved skin clearance and symptoma...
- Indication
Indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
- Associated Conditions
- Severe Plaque psoriasis, Moderate Plaque psoriasis
- Associated Therapies
- -
An Efficacy and Safety Study of CNTO1959 (Guselkumab) in the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
- First Posted Date
- 2015-01-22
- Last Posted Date
- 2019-10-24
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 21
- Registration Number
- NCT02343744
Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Active Psoriatic Arthritis (PsA)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-12-18
- Last Posted Date
- 2020-10-14
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 149
- Registration Number
- NCT02319759
A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-07-29
- Last Posted Date
- 2017-09-12
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 872
- Registration Number
- NCT02203032
Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2014-04-03
- Last Posted Date
- 2023-05-24
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 200
- Registration Number
- NCT02103361
- Locations
- 🇺🇸
University of California, San Diego, La Jolla, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath